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A b s t r a c t
Background: Cardiovascular diseases (CVDs) are the main cause of morbidity and mortality in developed countries. Despite 
the progress in diagnostics and treatment, it is expected that CVD will still be the main cause of death worldwide until at least 
2030. From 1991 CVD mortality in Poland systematically decreased, but it is still higher than the average in Western Europe. In 
2013 CVDs were the cause of 46% of all deaths in Poland (40.9% in men and 51.1% in women) and 26.9% of deaths among 
persons under 65 years of age. The epidemiologic assessment of prevalence, control and treatment of CVD risk factors, and 
monitoring of healthy behaviour and morbidity due to diseases like coronary artery disease, hypertension and diabetes is very 
important for health policy planning. The WOBASZ II is the newest Polish population based survey, performed in 2013–2014 to 
evaluate prevalence, control, treatment, and morbidity. The study was the continuation of WOBASZ (2003–2005).
Aim: To describe the goals and methods of the WOBASZ II study and to present the results of the recruitment.
Methods: The WOBASZ II study was planned as a cross-sectional survey of a random sample of Polish residents aged over 
20 years. The selection, using the National Identity Card Registry of the Ministry of Internal Affairs, was made as a three-stage 
sampling, stratified according to administrative units (voivodeships), type of urbanisation (commune), and gender. The study 
protocol consisted of a questionnaire used in face-to-face interviews, physical examination, and blood samples. WOBASZ II  
was coordinated by the Department of Epidemiology, Cardiovascular Diseases Prevention and Health Promotion of the 
Institute of Cardiology in Warsaw in cooperation with medical universities in Gdansk, Katowice, Krakow, Lodz, and Poznan.
Results: Out of 15,120 persons, 1557 persons were not eligible. Out of eligible persons, 6170 (2760 men and 3410 women) 
were examined (the response rate 45.5%). The highest response rates were observed in Warminsko-Mazurskie (64.2%), 
Zachodniopomorskie (58.1%), and Kujawsko-Pomorskie (53.1%).
Conclusions: The importance of the WOBASZ study for the monitoring of the health state of Polish society, and for the as-
sessment of prophylaxis efficiency and treatment of CVD and metabolic diseases, as well as for the evaluation of the actions 
in the field of health promotion, is difficult to overstate.
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INTRODUCTION
Cardiovascular diseases (CVD) due to arteriosclerosis, such as 
coronary heart disease (CHD) and stroke, are the main causes 
of morbidity, invalidity, and premature mortality in developed 
countries. It is estimated that despite the significant progress 
in diagnostics and treatment, in the majority of countries CVD 
will remain the main cause of mortality until at least 2030. 
Since 1991 mortality caused by CVD in Poland has been 
decreasing, but it still remains one of the highest in Europe [1]. 
In 2010 CVDs were the cause of 46.0% of all mortalities in 
Poland (40.8% in men and 51.8% in women) and the lead-
ing cause of premature mortalities (they constituted 26.9% of 
mortalities in people before the age of 65 years). Moreover, 
CVDs are not only the main cause of mortality, but also of 
morbidity and hospitalisation [2].
Although the etiopathogenesis of arteriosclerosis is not 
fully clarified, environmental factors related to improper life-
style (low physical activity, improper diet, tobacco smoking), 
leading to the increase of blood pressure, abnormal lipid 
and carbohydrate metabolism, or obesity play a dominant 
role in its development and progression. Analysis with the 
use of the IMPACT model and data originating from studies 
from the period 1991–2005 indicate that mortality caused 
by coronary artery disease has decreased in the last 20 years 
mainly thanks to changes in lifestyle (54% observed mortality, 
37.8% restorative medicine) [3, 4]. According to World Health 
Organisation (WHO) estimations, 3/4 of mortalities caused 
by CVD can be prevented by proper changes in lifestyle [5].
Apart from classic (hypertension, cigarette smoking, lipid 
disorders), the psychosocial risk factors of CVD are mentioned 
(depression symptoms [6], personality type, low level of social 
support, low socio-economic status [7]). These modifiable 
risk factors correlate with the frequency of occurrence of 
CHD, stroke, heart failure, peripheral arterial disease, and 
kidney failure [8]. Such conclusions were drawn based on the 
results of numerous studies, including the Framingham Heart 
Study, started in 1948, and nowadays the third generation 
of Framingham, Massachusetts participates in the study. It is 
believed that the term risk factor originates from the above-
mentioned study.
A multi-centre case-control study, INTER-HEART, 
conducted in 52 countries with participation of almost 
30,000 people demonstrated that six risk factors (hyperlipi-
daemia, cigarette smoking, hypertension, diabetes, abdominal 
obesity, and psycho-social factors) and three cardioprotective 
factors (consumption of fruit and vegetables, low alcohol con-
sumption, and regular physical activity) determined 90% of 
myocardial infarction in men and 94% of myocardial infraction 
in women. Such dependency was determined in all regions 
of the world, both in young as well as in older people [9]. 
Estimations conducted in numerous countries in the world 
indicate that a decrease of risk factor levels in a population 
gives better results in the reduction of cardiovascular mortality 
than an improvement in disease diagnostics and treatment. 
The epidemiological evaluation of prevalence, control, 
and treatment of CVD risk factors in a population, as well as 
monitoring of health behaviour and morbidity in relation to 
chronic diseases of social importance, such as: hypertension, 
CHD, or diabetes, should constitute the basis for the develop-
ment of rational and optimal (for both health and economic 
reasons) primary prevention programmes, directed toward 
the entire population (population strategy) and persons with 
high cardiovascular risk (high-risk strategy), bearing in mind 
secondary prevention.
The largest Polish epidemiological study evaluat-
ing the health condition of adult Poles is the WOBASZ 
(Wieloośrodkowe Ogólnopolskie BAdanie Stanu Zdrowia 
Ludności — Multi-Centre National Population Health Exami-
nation Survey) study, the first edition of which was carried out 
in 2003–2005 and the second in 2013–2014.
The aim of the present paper is to describe the goals and 
methods of the WOBASZ II study and to present the results 
of the recruitment.
Goals of the WOBASZ II study
The following main goals of the study were assumed:
1. Assessment of the current epidemiological situation of CVD 
in Poland and in individual voivodeships (monitoring of 
prevalence and control of CVD risk factors in the popula-
tion, as well as monitoring of health behaviour and mor-
bidity in relation to chronic diseases of social importance 
such as: hypertension, coronary artery disease, diabetes);
2. Assessment of changes in the period of 10 years in the 
range of prevalence and control of the CVD risk factors 
in Poland;
3. Integration into the CVD risk factor monitoring system in 
the European Union (EU) of states within the framework 
of the European Health Examination Survey (EHES), of 
which we are co-executors. 
The planned selection of a random sample and its size al-
lows for a reliable assessment of the epidemiological situation 
in the Polish population in the field of CVD threat, in each 
of the 16 voivodeships as well as in the country as a whole. 
The use of standardised methods accepted by the EU allows 
for the comparability of our results with the results obtained 
in the other states of the Community. 
It is expected that the prospective observation of the 
persons examined within the frameworks of the WOBASZ 
and WOBASZ II studies will enable future verification of the 
SCORE algorithm in the Polish population.
METHODS AND RESULTS
The methodology of the study (study protocol, training materi-
als, set of questionnaires, and instructions on each element of 
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the study) was based on the Manual of Operations handbook 
of the WHO MONICA Project [10] study, the protocol of the 
first WOBASZ [11] study, and the guidelines of the EU on 
the methodology of epidemiological surveys of CVD (EHES) 
[12]. Preparations for the second WOBASZ study edition had 
been started in 2012. 
The project was coordinated by the Department of Epi-
demiology, Cardiovascular Diseases Prevention, and Health 
Promotion of the Institute of Cardiology in Warsaw, and five 
academic centres participated in its implementation (Table 1). 
The study was accepted by the Field Bioethics Committee 
of the Institute of Cardiology in Warsaw. 
Organisation chart of the study and list of regional centres 
with their operation area is presented in Figures 1 and 2 and 
in Table 1.
Studied population and method of sample drawing
From the Polish population above the age of 19 years a sample 
of 15,200 people (from the electronic register — PESEL) of both 
genders was drawn at the Department of State Registers of the 
Ministry of the Interior. Drawing was conducted individually 
in each voivodeship. Sampling had three stages, stratified ac-
cording to voivodeships, type of communes, and gender. From 
the list of six-sign identifiers and names of national territorial 
units developed by the Central Statistical Office, a list of Pol-
ish communes was elaborated: 1847 small communes (below 
8000 citizens), 558 medium communes (8000–40,000 citi-
zens), and 102 large communes (over 40,000 citizens). For each 
voivodeship: two small communes, two medium communes, 
and two large communes were selected, the same as those 
that participated in the WOBASZ study (2003–2005), whereas 
the drawn sample of individual persons was independent. In 
each commune among persons above the age of 19 years, 
70 women and 70 men were drawn at the Department of State 
Registers of the Ministry of the Interior (from the electronic 
register — PESEL). The total (national) sample size amounted 
to 70 persons × two genders × six communes × 16 voivode-
ships = 13,440 persons. The sample included four communes 
from the voivodeship cities (Olsztyn, Opole, Szczecin, Zielona 
Gora). Furthermore, the study included citizens of the remaining 
12 voivodeship cities, which were not entered to the national 
sample drawn in the abovementioned method. In those cities 
an additional number of 70 men and women were drawn, i.e. 
12 × 70 × two genders = a total of 1680 persons in 12 cit-
ies. The total drawn sample size was 15,120 men and women. 
Figure 1. Organisation chart for WOBASZ II programme
Table 1. Academic centres implementing WOBASZ II study
Academic centre Regional coordinator Operation area voivodeship
Department of Preventive Medicine and Education  
Chair of Hypertension and Diabetology
Department of Arterial Hypertension and Diabetology, 
Medical University of Gdansk, Poland
Dr hab. n. med. T. Zdrojewski, 
prof. nadzw. GUMED
Kuyavian-Pomeranian (kujawsko-pomorskie) 
Pomeranian (pomorskie)
West Pomeranian (zachodnio-pomorskie)
3rd Department of Cardiology, Upper Silesian Centre of 
Cardiology, Medical University of Silesia, Katowice, Poland
Dr hab. n. med. K. Kozakiewicz Opole (opolskie)
Silesian (śląskie)
Department of Epidemiology and Population Studies,  
Institute of Public Health, Faculty of Health Sciences,  
Jagiellonian University Medical College, Krakow, Poland
Prof. dr hab. n. med. A. Pająk Lesser Poland (małopolskie)
Subcarpathian (podkarpackie) 
Holy Cross (świętokrzyskie)
Department of Preventive and Social Medicine,  
Medical University of Lodz, Poland
Dr hab. n. hum. W. Bielecki, 
prof. nadzw. UMED
Lower Silesian (dolnośląskie)
Lublin (lubelskie)
Lodz (łódzkie)
Department of Hypertension, Angiology, and Internal 
Medicine, Poznan University of Medical Sciences, Poland
Prof. dr hab. n. med. A. Tykarski Greater Poland (wielkopolskie)
Department of Epidemiology, Cardiovascular Disease 
Prevention, and Health Promotion, Institute of Cardiology, 
Warsaw, Poland
Prof. dr hab. n. med. W. Drygas Lubusz (lubuskie)
Masovian (mazowieckie)
Podlaskie (podlaskie)
Warmian-Masurian (warmińsko-mazurskie)
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2. Confirmation of personal data and obtaining respond-
ent-written consent for participation in the study (ques-
tionnaire test, physical, blood collection) and additional 
consent for blood collection for DNA isolation used in 
the genetic study;
3. Conducting interviews according to the provided ques-
tionnaires;
Eventually, 6170 patients (2760 men and 3410 women) were 
examined; reportability was 45.5% (Table 2).
Examination method
Assumed examination procedures included:
1. Sending invitations to persons drawn for participation 
in the study;
Table 2. Sample size and reportability according to voivodeships
Voivodeship Number of examined Number of unavailable Reportability (%)
01. Lower Silesian (dolnośląskie) 346 41 36.8
02. Kuyavian-Pomeranian (kujawsko-pomorskie) 488 61 53.1
03. Lublin (lubelskie) 333 51 35.8
04. Lubusz (lubuskie) 276 160 33.7
05. Lodz (łódzkie) 276 166 33.9
06. Lesser Poland (małopolskie) 388 166 47.9
07. Masovian (mazowieckie) 390 13 40.3
08. Opole (opolskie) 394 75 51.5
09. Subcarpathian (podkarpackie) 274 124 38.3
10. Podlaskie (podlaskie) 493 27 51.7
11. Pomeranian (pomorskie) 388 0 39.6
12. Silesian (śląskie) 402 140 47.9
13. Holy Cross (świętokrzyskie) 356 211 46.3
14. Warmian-Masurian (warmińsko-mazurskie) 517 35 64.2
15. Greater Poland (wielkopolskie) 435 160 53.0
16. West Pomeranian (zachodnio-pomorskie) 414 127 58.1
Total number of examined 6170 1557 45.5
Figure 2. Location of the drawn communes in WOBASZ II programme in categories of their populations’ sizes
< 8000
8000–40,000
> 40,000
Capital city
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4. Conducting blood pressure examinations and anthropo-
metric measurements;
5. Blood collection for biochemical tests and preparing 
blood serum samples for courier parcel in dry ice for the 
Central Laboratory in Warsaw;
6. Sending reports to the local coordinator on the course 
of the study regarding the persons who did not report at 
the examinations;
7. Sending letters with individual examination results to 
individual respondents. 
Scope of the examination
The examination included an interview, physical examination, 
and biochemical tests:
1. The interview according to the standard questionnaire:
a. Main questionnaire: 
 — socio-demographic data (age, marital status, 
education);
 — economic situation (main source of income, per 
capita income in family);
 — health knowledge;
 — physical activity at work and in leisure;
 — addictions (cigarette smoking, alcohol con-
sumption);
 — interviews on current and past diseases of the 
respondent, with special emphasis on hyperten-
sion, CHD (hospitalisations, history of coronary 
artery procedures), hyperlipidaemia, and diabe-
tes (pharmacological and non-pharmacological 
treatment);
 — family interview about CVD (infarction, stroke);
 — health care;
b. Questionnaire on the current use of medications 
(in the two weeks prior to the examination: name 
of medications, reason for taking medications, daily 
dose);
c. Questionnaire on diet: 
 — qualitative interview;
 — quantitative interview;
d. Psychological questionnaires (social support ques-
tionnaire of L. Berkman and L. Syme, Beck depres-
sion questionnaire, Geriatric Depression Scale, life 
quality questionnaire [WHOQoL]).
2. Physical examination: 
a. Blood pressure measurements;
b. Heart rate measurement: manual and automatic;
c. Anthropometric measurements (height, body mass, 
abdominal and hip circumference);
d. Electrocardiogram (optional);
3. Biochemical tests (glucose during fasting, total cholesterol, 
triglycerides, high-density lipoprotein [HDL]-cholesterol, 
low-density lipoprotein [LDL]-cholesterol);
4. Collection of blood sample for genetic study. 
Examinations were conducted depending on the local 
conditions — either in established stationary examination 
centres or in homes of the respondents during the time period 
07:00–14:00. Each person participating in the examination 
was informed in writing on the goal of the examination, its 
course (including anthropometric measurements and blood 
collection for biochemical test and possible DNA isolation). 
Respondents after familiarising themselves with the informa-
tion signed the consent for the examination along with its date. 
The majority of questions in the main questionnaire and 
psychological questionnaire were of the closed type (answers 
exhausted all the possibilities). Questionnaires on diet and 
taking medications were characterised by different types of 
questions and their coding method. 
Population diet assessment encompassed two methods: 
1) qualitative interview on the customary frequency of con-
suming selected product groups in the 2–3 months prior to 
the examination and 2) quantitative interview on consumption 
of products and dishes in the period 24 h prior to the exami-
nation. The customary frequency of selected product group 
consumption was estimated using the following consumption 
frequency categories: 7 times per week, 4–6 times per week, 
2–3 times per week, 1 time per week, 1–3 times per month, 
and less often than 1 time per month or never. In the quanti-
tative interview on the consumption of dishes and products 
in the period 24 h prior the examination, to determine the 
sizes of servings consumed an album was developed by the 
Food and Nutrition Institute in Warsaw with over 200 pho-
tographs of the most commonly consumed dishes, products, 
and drinks. Moreover, the interview included taking vitamin 
and and mineral compound supplements (name and dose). 
For the assessment of psychological characteristics three 
psychological questionnaires were used: 
1. L. Berkman and L. Syme social support questionnaire, 
the methodology of which follows the WHO MOPSY 
Study guidelines [13]. The questionnaire consisted of 
27 questions, determining relations of a person with 
other persons in difficult situations and in everyday life. 
Social support level was determined using special coding 
tables and an algorithm enabling determination of low 
and high social support;
2. The depression questionnaire of A.T. Beck (BDI) consisted 
of 21 questions, which, after encoding, determined the 
level of depression symptoms’ occurrence (from lack of 
symptoms to fully symptomatic depression) [14];
3. Quality of life questionnaire (WHOQoL) [15]. 
The measurement of height was performed after taking off 
shoes, depending on the place of examining the respondent, 
using a height measuring rod (examination at a communal 
centre) or a metre scale (at the respondent’s home) with the 
accuracy of 0.5 cm. Body weight measurement was performed 
(without shoes and outerwear) with an accuracy of 0.1 kg us-
ing mobile, certified Baurer scales. For the measurement of 
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blood pressure, automatic AND UA-631 devices were used, 
approved by Association for the Advancement of Medical 
Instrumentation (AAMI). Prior the blood pressure measure-
ment the examined person rested in the seating position for 
5 min and the researcher measured the arm circumference 
to select the proper cuff. The blood pressure and heart rate 
measurements were performed three times on the right arm, 
in the seating position, at 1-min intervals. For the assessment 
of pressure value, the average from the second and third 
measurement was assumed.
Laboratory test methodology
Collected blood was centrifuged at regional centres and frozen 
(at –20°C). Then, serums were transported in dry ice to the 
Central Laboratory “Diagnostyka” at the Institute of Cardiology 
in Warsaw, where all biochemical tests were conducted. The 
Central Laboratory holds a CDC certificate (Centre for Disease 
Control — Lipid Standardisation Programme) in Atlanta and 
a European certificate of quality RIQAS (Random International 
Quality Assessment Scheme). 
Analysis of lipid fraction and glucose concentrations were 
performed using a Cobas 6000 analyser by Roche with the 
use of agents from this company (Table 3).
Individual laboratory test results were entered in the 
Calculation Centre to the central computer database of all 
examined persons. Additionally, the results were sent to co-
operating regional centres, which sent them directly to each 
participant with appropriate commentary and recommenda-
tions. Moreover, serum samples were secured for storage for 
future analyses. 
General questionnaires were entered to the computer 
database at regional centres, whereas the remaining question-
naires (dietary, psychological, and medication card) — at the 
national centre for the entire national examined sample with 
the use of available software (EpiData, Excell, SAS, and others). 
Statistical estimation methods
For estimation of the event (risk factors) prevalence in in-
dividual voivodeships and the whole of Poland, a direct 
standardisation will be implemented, following the Polish 
population structure as of 31.12.2013 (Table 4). The analysis 
will cover the following age groups: 20–34, 35–44, 45–54, 
55–64, 65–74, and 75+ years. The comparison of standard-
ised coefficients between study I and study II will be limited 
to the age group 20–74 years (the age range of the WOBASZ 
study) (Table 4).
Number of examined and reportability
Data collection was conducted from 02.09.2013 to 
23.11.2014. Considering the collected and analysed data 
from 16 voivodeships (108 communes) 6170 persons were 
examined. The number of examined in each of the voivode-
ships is presented in Table 2. From the drawn sample of 
15,120 persons (108 communes × 140), as a result of the 
conducted study 1557 cases of unavailable persons were 
identified, i.e. deceased or unavailable at the time of the 
study (away from home, state of health did not allow for 
participation in the study, or could not be contacted). After 
verification the drawn sample, i.e. the number of available 
persons, was 13,563. A total of 6170 persons reported to the 
Table 3. Biochemical analysis methodology
Type of analysis Laboratory method
Total cholesterol concentration Enzymatic-colorimetric method with cholesterol esterase, with the use cholesterol oxidase (CHOD)  
and peroxidase (agent: Cholesterol Gen. 2)
HDL-cholesterol concentration Uniform colorimetric enzymatic method, analysis with the use of cholesterol esterase  
and cholesterol oxidase affiliated from PEG (polyethylene glycol) to amine groups  
(agent: HDL-cholesterol plus third generation) 
LDL-cholesterol concentration Uniform colorimetric enzymatic method, analysis with the use of cholesterol oxidase  
(agent: LDL-cholesterol plus second generation) 
Triglyceride concentration Enzymatic-colorimetric method with glycerophosphate oxidase and 4-aminophenazone  
(agent: Triglycerides)
Glucose concentration Enzymatic method with hexokinase, with the use of glucose 6-phosphate dehydrogenase (G6PDH) 
(agent: Glucose HK Gen 3)
HDL — high-density lipoprotein; LDL — low-density lipoprotein 
Table 4. Structure of the Polish population as of 31.12.2013
Age: 0–19 20–34 35–44 45–54 55–64 65–74 75+
N 7 895 735 8 886 958 5 550 521 4 932 856 5 556 981 3 042 112 2 630 496
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study. Reportability was defined as the ratio of the number of 
examined persons to the number of persons available in the 
study. Table 2 includes reportability coefficients in individual 
voivodeships and in the entire sample. In the entire sample of 
the studied Polish population the reportability was 45.5%. The 
highest reportability was achieved in the Warmian-Masurian, 
West Pomeranian, and Greater Poland voivodeships (Table 2).
DISCUSSION
The Multi-centre National Population Health Examination 
Survey WOBASZ is the largest representative epidemiological 
study analysing health state, prevalence of risk factors, and 
health behaviour of society in Poland. Consecutive editions 
of the study: WOBASZ and WOBASZ II allow for the assess-
ment of changes in the analysed coefficients in the period 
of 10 years. In this period gradual changes of population 
structure, socioeconomic situation, and lifestyle have taken 
place. Following trends prevailing in the majority of developed 
countries, the Polish population has aged, and the average 
life expectancy has increased (2006: 71.5 years for men and 
80 years for women; 2014: 73 years for men and 81.6 for 
women) [16]. The epidemiological situation in the field of 
CVD has also changed. 
The results of the WOBASZ study (2003–2005) as well 
as the NATPOL 2011 study, published in international and 
national literature, indicate high prevalence of hyperlipidae-
mia, hypertension, obesity, metabolic syndrome, and diabetes 
and high level of global risk within the population of adults 
in Poland [17, 18]. Following the arrangements of the Project 
Steering Committee, first results of WOBASZ II study will be 
officially presented during a special session of the VII Confer-
ence “Kardiologia Prewencyjna” (Preventive Cardiology) in 
Krakow, November 2015. Moreover, it has been determined 
that at the turn of 2015 and 2016 the first WOBASZ II study 
results will be published in international literature. The first 
series of approximately 15–20 papers will cover health state, 
prevalence of the most important risk factors, health behav-
iour, and multiannual change trends of the analysed factors.
The issue remaining to be discussed is reportability in 
the WOBASZ II study, which did not exceed 50%. Although 
significantly lower than in the first study (76.9%), it follows 
current trends in European studies, current expectations, 
and recommendations of international expert groups. In the 
scientific studies, reportability is influenced by numerous fac-
tors such as: age of the examined (reportability increases with 
age up to approximately 65 years, and in the older groups 
decreases, especially among women), gender (reportability is 
higher among women), geographical region, and method of 
data collection (this especially regards questionnaire tests). In 
the 1980s reportability in the studies of health state and survey 
tests was at the level of 80%, but nowadays it rarely exceeds 
40–50% [19, 20]. During the European Health Examination 
Survey Pilot Study, conducted in the period 2009–2012 in 
12 European countries, including Poland, reportability ranged 
from 16% to 57% among men and from 31% to 74% among 
women [21]. The phenomenon of decreasing reportability 
in studies of health state may be influenced by the increas-
ing number of both scientific studies, as well as telephone 
marketing research [22].
The latest European guidelines (EHES) suggest that for the 
conducting of national screening of people in the age range 
25–64 years, a sample of 4000 persons is sufficient [23]. The 
EHES recommendations are similar to the STEPS recommen-
dations, according to which, to obtain representative results 
for a general population, a sample with an equal number of 
men and women in each of the 10-year age groups should 
be selected (500 in each age group) [24]. 
CONCLUSIONS
As mentioned above, the results of the WOBASZ II study are 
the subject of publications currently being prepared. We are 
certain that the results of this newest, representative national 
study and comparison with the results of the WOBASZ study, 
conducted in 2003–2005, will be very interesting, and not 
only for cardiology circles. The importance of the WOBASZ 
study for the monitoring of the health state of Polish society, 
assessment of prophylaxis efficiency and treatment of CVD 
and metabolic diseases, as well as for the evaluation of the 
actions in the field of health promotion, is difficult to overstate.
An additional value resulting from the WOBASZ pro-
gramme is the close cooperation of the leading research 
centres in Poland: epidemiologists, clinicians, specialists in the 
field of public health and health promotion, and the possibility 
to share experience and improve practical skills, particularly 
among young scientists. 
The WOBASZ II project was financed from the financial 
resources at the disposal of the Minister of Health within the 
framework of the health programme entitled: National Pro­
gram for the Equalisation of Accessibility to Cardiovascular 
Disease Prevention and Treatment for 2010–2012 POL­
KARD — goal: Analyses and epidemiology — “Monitoring 
of the epidemiological situation in Poland in the field of 
cardiovascular diseases.”
Steering Committee of WOBASZ and WOBASZ II
Dr hab. n. med. Grażyna Broda, prof. nadzw. IK , Department 
of Epidemiology, Cardiovascular Disease Prevention and 
Health Promotion, Institute of Cardiology, Warsaw — Re-
search Coordination Centre WOBASZ and WOBASZ II — till 
2013), prof. dr hab. med. Wojciech Drygas, Department of 
Epidemiology, Cardiovascular Disease Prevention and Health 
Promotion, Institute of Cardiology, Warsaw and Department 
of Social and Preventive Medicine, Medical University of 
Lodz — Research Coordination Centre WOBASZ II — since 
2013, dr hab. n. hum. Wojciech Bielecki, prof. nadzw. UMED, 
Department of Social and Preventive Medicine, Medical Uni-
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versity of Lodz — WOBASZ and WOBASZ II, prof. dr hab. n. 
med. Jerzy Głuszek, Department of Hypertension, Angiology 
and Internal Medicine, Poznan University of  Medical Sci-
ences — WOBASZ, dr hab. n. med. Krystyna Kozakiewicz, 
3rd Department of Cardiology, Medical University of  Silesia, 
Katowice — WOBASZ and WOBASZ II, prof. dr hab. n. med. 
Andrzej Pająk, Department of Epidemiology and Population 
Studies, Institute of Public Health, Faculty of Health Sciences, 
Jagiellonian University Medical College, Krakow — WOBASZ 
and WOBASZ II, prof. dr hab. n. med. Stefan Rywik , Depart-
ment of Epidemiology, Cardiovascular Disease Prevention and 
Health Promotion, Institute of Cardiology, Warsaw — Re-
search Coordination Centre WOBASZ, prof. dr hab. n. med. 
Andrzej Tykarski, Department of Hypertension, Angiology 
and Internal Medicine, Poznan University of Medical Sci-
ences — WOBASZ and WOBASZ II, prof. dr hab. n. med. 
Bogdan Wyrzykowski, Department of Arterial Hypertension 
and Diabetology Medical University of Gdansk — WOBASZ 
i WOBASZ II, dr hab. n. med. Tomasz Zdrojewski, prof. nadzw. 
GUMED, Department of Arterial Hypertension and Diabe-
tology, Department of Preventive Medicine and Education 
Medical University of Gdansk — WOBASZ and WOBASZ II
Academic centres implementing WOBASZ  
and WOBASZ II (in alphabetical order)
Gdańsk: Department of Arterial Hypertension and Diabetolo-
gy, Department of Preventive Medicine and Education Medical 
University of Gdansk: Piotr Bandosz (WOBASZ and WOBASZ II), 
Agata Ignaszewska-Wyrzykowska (WOBASZ II), Hanna 
Jasiel-Wojculewicz (WOBASZ), Anna Korzon-Burakowska 
(WOBASZ II), Aleksandra Puch-Walczak (WOBASZ and 
WOBASZ II), Marcin Rutkowski (WOBASZ and WOBASZ II), 
Paweł Szpakowski (WOBASZ), Łukasz Wierucki (WOBASZ II), 
Bogdan Wyrzykowski (WOBASZ and WOBASZ II), 
Tomasz Zdrojewski (WOBASZ and WOBASZ II) and Zenon 
Jakubowski — University Clinical Centre Gdansk (WOBASZ) 
and Alicja Utracka — Clinical Central Laboratory University 
Clinical Centre Gdansk (WOBASZ II)
Katowice: 3rd Department of Cardiology, Medical Univer-
sity of Silesia, Katowice: Krystyna Kozakiewicz (WOBASZ and 
WOBASZ II), Paweł Nadrowski (WOBASZ II), Ewa Podolecka 
(WOBASZ II), Michał Tendera (WOBASZ)
Kraków: Department of Epidemiology and Popula-
tion Studies, Institute of Public Health, Faculty of Health 
Sciences, Jagiellonian University Medical College, Krakow: 
Elżbieta Brzezicka (WOBASZ II), Agnieszka (Doryńska) Besala 
(WOBASZ II), Maciej Górkiewicz (WOBASZ), Ewa Kawalec 
(WOBASZ), Dorota Kurek (WOBASZ), Witosława Misio-
wiec (WOBASZ and WOBASZ II), Andrzej Pająk (WOBASZ 
and WOBASZ II), Urszula (Biela) Stepaniak (WOBASZ and 
WOBASZ II), Bożena Szmatka (WOBASZ), Roman Topór-
Mądry (WOBASZ and WOBASZ II), Ewa (Dojka) Wiercińska 
(WOBASZ)
Łódź: Department of Social and Preventive Medicine, 
Medical University of Lodz: Wojciech Bielecki (WOBASZ 
and WOBASZ II), Beata Bill-Bielecka (WOBASZ II), Wojciech 
Drygas (WOBASZ and WOBASZ II), Elżbieta Dziankowska- 
-Zaborszczyk (WOBASZ and WOBASZ II), Krystyna Kaczmarczyk-
-Chałas (WOBASZ), Magdalena Kwaśniewska (WOBASZ and 
WOBASZ II), Aldona Morga (WOBASZ), Małgorzata Pikala 
(WOBASZ and WOBASZ II), Małgorzata Pepińska (WOBASZ II), 
Ewa Rębowska (WOBASZ and WOBASZ II)
Poznań: Department of Hypertension, Angiology, and 
Internal Medicine, Poznan University of Medical Sciences: 
Jerzy Głuszek (WOBASZ), Arkadiusz Niklas (WOBASZ II), 
Anna Flotyńska (WOBASZ II), Anna Posadzy-Małaczyńska 
(WOBASZ), Andrzej Tykarski (WOBASZ and WOBASZ II).
Warszawa: Department of Epidemiology, Cardiovascular 
Disease Prevention, and Health Promotion, Institute of Cardiol-
ogy, Warsaw: Anita Aranowska (WOBASZ II),  Grażyna Broda 
(WOBASZ and WOBASZ II), Danuta Bolek (WOBASZ and 
WOBASZ II), Agnieszka Borowiec (WOBASZ II), Bogusława 
Brzosko (WOBASZ and WOBASZ II), Alicja Cicha-Mikołajczyk 
(WOBASZ II), Wojciech Drygas (WOBASZ and WOBASZ II), 
Katarzyna Istynowicz (WOBASZ II), Paweł Kurjata (WOBASZ 
and WOBASZ II), Izabella Lignowska (WOBASZ II), Walerian 
Piotrowski (WOBASZ and WOBASZ II), Aleksandra Piwońska 
(WOBASZ and WOBASZ II), Jerzy Piwoński (WOBASZ and 
WOBASZ II), Maria Polakowska (WOBASZ and WOBASZ II), 
Paweł Porębski (WOBASZ II), Zofia Słońska (WOBASZ II), 
Elżbieta Sygnowska (WOBASZ and WOBASZ II), Danuta 
Szcześniewska (WOBASZ and WOBASZ II), Anna Waśkiewicz 
(WOBASZ and WOBASZ II), Jadwiga Zabielewicz (WOBASZ 
and WOBASZ II)
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Wieloośrodkowe Ogólnopolskie Badanie  
Stanu Zdrowia Ludności (badanie WOBASZ II): 
założenia, metody i realizacja
Wojciech Drygas1, 2, Arkadiusz A. Niklas3, Aleksandra Piwońska1, Walerian Piotrowski1, Anna Flotyńska3, 
Magdalena Kwaśniewska2, Paweł Nadrowski4, Aleksandra Puch-Walczak5, Krystyna Szafraniec6,  
Wojciech Bielecki2, Krystyna Kozakiewicz4, Andrzej Pająk5, Andrzej Tykarski3, Tomasz Zdrojewski6
1Zakład Epidemiologii, Prewencji Chorób Układu Krążenia i Promocji Zdrowia, Instytut Kardiologii, Warszawa
2Katedra Medycyny Społecznej i Zapobiegawczej, Uniwersytet Medyczny, Łódź
3Katedra i Klinika Hipertensjologii, Angiologii i Chorób Wewnętrznych, Uniwersytet Medyczny, Poznań
4III Klinika Kardiologii, Śląski Uniwersytet Medyczny, Katowice
5Zakład Epidemiologii i Badań Populacyjnych, Instytut Zdrowia Publicznego, Wydział Nauk o Zdrowiu, Uniwersytet Jagielloński  
Collegium Medicum, Kraków
6Zakład Prewencji i Dydaktyki, Gdański Uniwersytet Medyczny, Gdańsk
S t r e s z c z e n i e
Wstęp: Od 1991 r. umieralność z powodu chorób układu sercowo-naczyniowego (CVD) w Polsce maleje, ale nadal jest jedną 
z wyższych w Europie. W 2013 r. CVD stanowiły 46,0% wszystkich zgonów w Polsce (40,9% wśród mężczyzn i 51,1% wśród ko-
biet) oraz były wiodącą przyczyną zgonów przedwczesnych (26,9% zgonów wśród osób przed 65. rż.). Ocena epidemiologiczna 
dotycząca rozpowszechniania, kontroli i leczenia czynników ryzyka CVD w populacji oraz monitorowanie zachowań zdrowotnych 
i chorobowości w odniesieniu do przewlekłych chorób o znaczeniu społecznym, takich jak nadciśnienie, choroba wieńcowa czy 
cukrzyca są bardzo istotne z punktu widzenia planowania polityki zdrowotnej, w tym programów prewencji pierwotnej i wtórnej. 
Najnowszym badaniem przekrojowym w Polsce jest WOBASZ II realizowane w latach 2013–2014, którego celem była ocena 
rozpowszechniania i kontroli czynników ryzyka CVD w populacji oraz monitorowanie zachowań zdrowotnych i chorobowości 
w odniesieniu do przewlekłych chorób o znaczeniu społecznym, takich jak: nadciśnienie, choroba wieńcowa, cukrzyca. Powyższy 
projekt stanowił kontynuację badania WOBASZ (2003–2005).
Cel: Celem niniejszej publikacji było przedstawienie założeń i celów oraz metodyki badania WOBASZ II.
Metody: Projekt WOBASZ II zaplanowano jako badanie próby losowej populacji polskiej w wieku 20 lat i starszych. Schemat loso-
wania próby był dwustopniowy, stratyfikowany ze względu na województwa i kategorie gmin. Operatem losowania był powszechny 
elektroniczny system ewidencji ludności PESEL. Każdy respondent, po wyrażeniu zgody, został poddany badaniu kwestionariuszo-
wemu, przedmiotowemu (3-krotne pomiary ciśnienia tętniczego krwi, pomiar masy ciała i wzrostu) oraz miał pobraną krew w celu 
oznaczenia lipidogramu i stężenia glukozy na czczo, a także w celu izolacji DNA dla badań genetycznych. Projekt WOBASZ II 
koordynował zespół Zakładu Epidemiologii, Prewencji Chorób Układu Krążenia i Promocji Zdrowia Instytutu Kardiologii w War-
szawie we współpracy z uniwersytetami medycznymi w Gdańsku, Katowicach, Krakowie, Łodzi i Poznaniu.
Wyniki: Z wylosowanej w 16 województwach próby, liczącej 15 120 osób, w wyniku przeprowadzonego badania stwierdzono 
1557 przypadków osób niedostępnych do badania. Spośród pacjentów dostępnych zgłosiło się 6170 osób (2760 mężczyzn 
i 3410 kobiet; zgłaszalność 45,5%). Najwyższą zgłaszalność zanotowano w województwie warmińsko-mazurskim (64,2%), zachod-
niopomorskim (58,1%) oraz kujawsko-pomorskim (53,1%).
Wnioski: Wyniki badania WOBASZ II, których publikację przewidziano na przełomie lat 2016/2017, będą miały istotne znaczenie 
dla analizy zmian w rozpowszechnieniu czynników ryzyka, skuteczności działań w zakresie promocji zdrowia i zapobiegania choro-
bom przewlekłym oraz dla oceny skuteczności leczenia m.in.: nadciśnienia tętniczego i hiperlipoproteinemii w Polsce w XXI wieku.
Słowa kluczowe: czynniki ryzyka, choroby układu sercowo-naczyniowego, badanie przekrojowe, Polska, WOBASZ
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